Who should own the knowledge that underpins AI technology? 
Judge Orders Trump to Restore White House Access for CNN, MS NOW and Politico 
Trump Administration Removes Confederate Memorial Criticism From Arlington Website 
U.S. Imposes New Visa Restrictions Over South Africa Policies 
Netanyahu Takes Aim at Mamdani as Israel Election Nears 
White House Bars CNN, MS NOW and Politico Reporters 
Trump Administration Plans Faster FDA Reviews for Smoke-Free Nicotine Products 
Russian Missile and Drone Attack on Kyiv Kills Two, Damages Maternity Hospital 
Abbas Reaffirms November 28 Palestinian Elections 
OpenAI Agent Breaches Australia Medicare Data Portal 
China Reviews Broadcom Switch Use in State Data Centres 
Australia Tightens Student Visa Rules, Targets Migration Cut by 2028 
Ghana Says Western Support Growing for Slave Trade Reparations 
US Resumes Immigrant Visa Processing for Hungary, Poland 
FAA Allows Boeing to Sell 35 More 777F Freighters Beyond 2028 
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe 
US Officials Split Over Response to Israeli West Bank Settlements 
Add as a preferred source on Google
President Donald Trump revealed plans for a significant new tariff on pharmaceutical imports, aiming to encourage drug companies to relocate production back to the United States. Speaking at a National Republican Congressional Committee event on Tuesday, Trump emphasized the need to strengthen domestic manufacturing and reduce reliance on foreign drug suppliers.
The proposed pharmaceutical tariff, which he described as "major," is intended to serve as an economic incentive for pharmaceutical firms to invest in U.S.-based operations. Trump argued that bringing drug manufacturing back to American soil would not only create jobs but also enhance national security by reducing dependency on international supply chains, particularly in critical sectors like healthcare.
Although specific details about the tariff’s scope, rate, or timeline have not yet been disclosed, Trump’s announcement aligns with his broader “America First” economic strategy, which focuses on reshoring industries and protecting U.S. jobs through trade measures.
Pharmaceutical imports have long been a point of contention, with critics warning about supply chain vulnerabilities and the outsourcing of essential drug production. Trump’s latest statement signals a renewed push to reshape the U.S. pharmaceutical industry through trade policy, especially as concerns about global health security and drug shortages persist.
The pharmaceutical sector and international trade partners will be closely watching for official policy announcements in the coming weeks. If implemented, the tariff could have wide-reaching implications for drug pricing, international trade relations, and domestic pharmaceutical investments.
As the 2024 election cycle heats up, Trump’s proposal underscores his continued focus on economic nationalism and U.S. manufacturing revival. The move may energize his political base and further distinguish his policy approach from other candidates in the race.
